Episode
Benchmark’s Bill Gurley, CoreWeave Strikes Deal with Anthropic, New Treatment for Pancreatic Cancer 4/10/26
- Podcast
- CNBC’s “Money Movers”
- Published
- Apr 10, 2026
- Duration seconds
- 2542
- Processing state
not_requested- Canonical source
- https://www.cnbc.com
Actions
POST https://stenobird.com/v1/public/podcasts/cnbc-s-money-movers-6706747/episodes/benchmark-s-bill-gurley-coreweave-strikes-deal-with-anthropic-new-treatment-for-pancreatic-cancer-4-10-26/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/cnbc-s-money-movers-6706747/benchmark-s-bill-gurley-coreweave-strikes-deal-with-anthropic-new-treatment-for-pancreatic-cancer-4-10-26.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Concerns grow over AI’s cyber security risks with the Fed Chair and Treasury Secretary meeting with bank executives. Legendary investor Bill Gurley lays out his thoughts on the rapidly changing landscape. Then CoreWeave inking yet another deal with a major AI player, this time Anthropic. We look at the bull and bear cases for the stock. And a new treatment from Revolution Medicines targets one of the deadliest forms of cancer, pancreatic.